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Abstract
Background: RAI3 is an orphan G-protein coupled receptor (GPCR) that has been associated with malignancy
and may play a role in the proliferation of breast cancer cells. Although its exact function in normal and malignant
cells remains unclear and evidence supporting its role in oncogenesis is controversial, its abundant expression on
the surface of cancer cells would make it an interesting target for the development of antibody-based
therapeutics. To investigate the link with cancer and provide more evidence for its role, we carried out a
systematic analysis of RAI3 expression in a large set of human breast cancer specimens.
Methods: We expressed recombinant human RAI3 in bacteria and reconstituted the purified protein in
liposomes to raise monoclonal antibodies using classical hybridoma techniques. The specific binding activity of the
antibodies was confirmed by enzyme-linked immunosorbent assay (ELISA), western blot and
immunocytochemistry. We carried out a systematic immunohistochemical analysis of RAI3 expression in human
invasive breast carcinomas (n = 147) and normal breast tissues (n = 44) using a tissue microarray. In addition, a
cDNA dot blot hybridisation assay was used to investigate a set of matched normal and cancerous breast tissue
specimens (n = 50) as well as lymph node metastases (n = 3) for RAI3 mRNA expression.
Results: The anti-RAI3 monoclonal antibodies bound to recombinant human RAI3 protein with high specificity
and affinity, as shown by ELISA, western blot and ICC. The cDNA dot blot and immunohistochemical experiments
showed that both RAI3 mRNA and RAI3 protein were abundantly expressed in human breast carcinoma.
However, there was no association between RAI3 protein expression and prognosis based on overall and
recurrence-free survival.
Conclusion: We have generated a novel, highly-specific monoclonal antibody that detects RAI3 in formaldehyde-
fixed paraffin-embedded tissue. This is the first study to report a systematic analysis of RAI3 expression in normal
and cancerous human breast tissue at both the mRNA and protein levels.
Published: 24 June 2009
BMC Cancer 2009, 9:200 doi:10.1186/1471-2407-9-200
Received: 16 December 2008
Accepted: 24 June 2009
This article is available from: http://www.biomedcentral.com/1471-2407/9/200
© 2009 Jörißen et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 15
(page number not for citation purposes)
BMC Cancer 2009, 9:200 http://www.biomedcentral.com/1471-2407/9/200Background
RAI3 belongs to the family of G-protein coupled receptors
(GPCRs) that are the largest and most abundant receptor
family in mammals consisting of more than a thousand
members. They are characterised by the characteristic
structure of an extracellular ligand-binding domain, and
internal seven-pass transmembrane domain (7-TM) con-
sisting of seven membrane-spanning α-helices, and an
internal C-terminal domain [1]. The intracellular C-termi-
nus is thought to interact with G-proteins that bind guani-
dine-nucleotides (GDP, GTP) and can activate
downstream effectors such as adenyl cyclases, phospholi-
pases, phosphodiesterases and ion channels when an ago-
nist binds to the extracellular portion of the receptor [2].
GPCRs activate numerous signal transduction cascades
and thus play pivotal role in the regulation of many phys-
iological and pathological processes, including cell
growth and differentiation. For this reason, they are
regarded as valuable and interesting drug targets for the
numerous human diseases that have been associated with
dysfunctional GPCRs, and researchers are actively seeking
ligands for the so-called orphan GPCRs whose role in
physiology and disease has yet to be determined [1]. The
abundant cell surface expression and rapid internalisation
of GPCRs make them particularly appropriate targets for
antibody-based therapeutics.
RAI3, also known as GPRC5A and RAIG-1, was originally
identified as an all-trans-retinoic acid inducible gene [3].
The corresponding orphan GPCR is localised at the
plasma membrane and in intracellular vesicles, and is pre-
dominantly expressed in normal lung tissue whereas only
low level expression has been detected in other tissues
such as liver, pancreas, colon and mammary glands [3-5].
Although RAI3 is thought to regulate cell proliferation,
the exact molecular mechanism is not understood and is
a matter of some controversy [5-8]. RAI3 was initially con-
sidered to be a potential tumour-suppressor gene because
of its presumed regulation by retinoids, which have
shown to influence tumourigenesis and exert significant
therapeutic and preventative effects on tumours. This
hypothesis has recently been supported by data from a
knock-out mouse model, which showed mice lacking the
gene were more likely than wild type mice to develop lung
tumours at 1–2 years of age [8]. RT-PCR analysis of differ-
ent lung cancer types also showed higher RAI3 mRNA lev-
els in normal tissue adjacent to tumour tissue. However,
other findings indicate that higher levels of RAI3 expres-
sion promote tumour growth, e.g. a cDNA microarray
study in which RAI3 was shown to be upregulated in
breast cancer specimens [9]. In a further study, RAI3 over-
expression was observed in 19 of 25 breast cancer samples
compared to matched normal mammary gland tissues
and in 6 of 11 breast cancer cell lines. In addition, siRNA
silencing of RAI3 reduced proliferation of the human
embryonic kidney cell line HEK293 and the breast cancer
cell lines MCF-7 and T47D [5]. In RAI3-transfected Nthy
cells, a human thyroid follicular epithelial cell line, RAI3
siRNA actually induced apoptosis [7]. Further studies
have suggested RAI3 is a growth-promoting gene that may
be involved in cell cycle regulation with a peak expression
in G1 phase, as analysed in the human cervical epithelial
tumour cell line (HeLa). The growth-promoting effect of
RAI3 is further underlined by the finding that RAI3 is a
p53-transcriptional target gene [6].
The role of RAI3 in cancer and its localisation in the
plasma membrane make this molecule an interesting
potential target for antibody-mediated therapy. We report
for the first time the development of a monoclonal anti-
human RAI3 antibody, termed Mab 24 2.3, that binds
with high specificity and affinity to RAI3 in ELISAs, west-
ern blot and as well in situ to the target on transfected
HEK293T cells and paraffin-embedded tissue sections.
The development of this antibody is of general interest for
potential diagnostic use in routine pathological investiga-
tions, but it could be used in a therapeutic context. As
RAI3 was found upregulated in human breast cancer we
decided to use the antibody to determine the abundance
of RAI3 on a large panel of human breast carcinomas and
normal breast tissues, and compare this with expression
analysis at the mRNA level. This is the first systematic
analysis of RAI3 expression in a large cohort of human
breast carcinomas and normal breast tissues both at the
mRNA and the protein level. We evaluated the results
looking for correlations with hormone receptor status,
HER2 status and patient survival data. The impact of our
data on prognosis and treatment of breast cancer are dis-
cussed.
Methods
RAI3 antigen expression and purification
The RAI3 cDNA was cloned in pGEX2a as an in-frame
fusion with an N-terminal GST tag and a C-terminal hex-
ahistidine tag as described previously [10]. The N-termi-
nal fusion abolishes the toxicity observed when
eukaryotic membrane proteins are expressed in E. coli by
promoting the direction of protein to inclusion bodies
which results in high-level production [10]. The construct
was introduced into Escherichia coli BL21, and 1 l of LB
medium containing 100 mg/l ampicillin was inoculated
with 10 ml of an overnight culture containing 50 mg/l
carbenicillin and shaken at 37°C. When the culture
reached an A600 of 0.80, protein expression was induced
by adding 0.1 mM of isopropyl-β-D-thiogalactoside for 4
h. Cells were harvested by centrifugation, resuspended in
10 ml ice-cold 20 mM Tris/HCl pH 7.5 and frozen at -
20°C. After thawing to 4°C and adding EDTA and dithio-
threitol (DTT) each to a final concentration of 1 mM, the
cell suspension was stirred for 10 min, disrupted byPage 2 of 15
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(Emulsiflex C5, Avestin Inc. Canada), supplemented to a
final concentration of 50 mM EDTA, 10 mg/ml Triton X-
100, and stirred for a further 30 min. Insoluble protein
was pelleted by centrifugation for 45 min at 48400 g. The
pellet was washed in 20 mM sodium phosphate, 150 mM
NaCl (pH 7.0) containing 1 mM DTT, centrifuged as
above and finally resuspended in 10 ml of the same
buffer. This suspension, referred to as "inclusion bodies",
although it includes the bacterial membranes, was stored
at -20°C.
Inclusion bodies were thawed on ice, pelleted by centrifu-
gation for 30 min at 46500 g at 4°C, resuspended in 5 ml
of 25 mM Tris/HCl pH 8.5, 150 mM NaCl and incubated
at room temperature under reducing conditions (5 mM
DTT) for 1 h. Ten volumes of 10 mg/ml lauroyl sarcosine
(LS) in 25 mM Tris/HCl (pH 8.5), 250 mM NaCl were
added and the sample was sonicated for 1 min using a tip
sonicator on ice. After stirring at room temperature for 2 h
and at 4°C for 1 h, the C-terminal GST tag was cleaved
with 10 U thrombin per ml of inclusion bodies for 1 h at
4°C. To abort cleavage, we added 200 μM phenylmethyl-
sulphonyl fluoride and an additional 10 mg/ml LS. The
insoluble fraction was removed by centrifugation at
38500 g, 4°C. For RAI3 purification, the supernatant was
incubated overnight at 4°C with 1.5 ml Ni-NTA Super-
flow (Qiagen, Hilden, Germany) per ml of inclusion bod-
ies equilibrated in 20 mg/ml LS, 25 mM Tris/HCl (pH
8.5), 250 mM NaCl.
The Ni-matrix was packed into a column and washed at a
flow rate of 2 cm/h with (i) three column volumes (CV)
of 20 mM Tris/HCl (pH 8.5), 250 mM NaCl, 10 mM β-
mercaptoethanol (βME), 10 mg/ml n-tetradecylphospho-
choline (Fos14, Anatrace, Maumee, OH), (ii) 10 CV of 20
mM Tris/HCl (pH 8.5), 250 mM NaCl, 10 mM βME, 1
mg/ml Fos14, 0.2 mg/ml Folch Lipid Fraction I (Sigma)
and (iii) one CV of 20 mM Tris/HCl (pH 7.5), 250 mM
NaCl, 1 mM glutathione (GSH), 0.1 mg/ml Fos14. Pro-
tein was eluted in 20 mM Tris, 250 mM NaCl, 1 mM GSH,
300 mM imidazole, 0.1 mg/ml Fos14 adjusted to pH 7.5.
Protein-containing fractions were pooled and DTT was
added to 10 mM. Monomeric RAI3 was isolated by apply-
ing the concentrated pooled fraction to a Superdex 200
HiLoad XK 16/60 gel filtration column (GE Healthcare,
Freiburg, Germany) run in 20 mM HEPES/NaOH (pH
7.0), 200 mM NaCl, 0.25 mg/ml Fos14, 1 mM DTT at 1
ml/min. Monomeric RAI3-containing fractions were
pooled, and concentrated to 1 mg/ml.
RAI3 reconstitution into liposomes
Purified RAI3 was dialysed against 100 volumes of 100
mM boric acid/NaOH (pH 9.5), 0.1 mg/ml Fos14 at 4°C
prior to reconstitution. A lipid blend was obtained by dis-
solving Folch Lipid Fraction I, phosphatidyl eth-
anolamine from sheep brain (Sigma) and cholesterol at a
ratio of 40:32:28 in chloroform. After removal of the chlo-
roform under vacuum over night the lipid was first resus-
pended in water at 10 mg/ml and then partially dissolved
in CHAPS by incubating for 1 h at room temperature with
a CHAPS to lipid ratio of 3:1 and a lipid concentration of
7.5 mg/ml. CHAPS and SDS at final concentrations of 5
and 0.1 mg/ml respectively were added to the dialysed
RAI3. After 10 min, 70 mM KCl was added and the RAI3
solution was merged with 1.3 times the volume of the
lipid/CHAPS mixture. This mixture was rotated end-over-
end over night at 4°C. Detergent was then extracted by
adding an equal volume of fresh Calbiosorb beads, which
had been thoroughly washed with water and drained, fol-
lowed by end-over-end rotation for 3 h at 4°C. Beads were
removed using a fritted plastic column and proteolipo-
somes were harvested by centrifugation for 30 min at
100,000 g, 4°C. The resulting pellet was resuspended in
20 mM HEPES/NaOH (pH 7.0), 150 mM NaCl at a theo-
retical protein concentration of 1 mg/ml. Aliquots were
frozen in liquid nitrogen and stored at -80°C. BALB/c
mice were immunised using the RAI3 antigen reconsti-
tuted in liposomes. All additional in vitro experiments
were also performed with the soluble protein prior to
liposome reconstitution.
Production of monoclonal antibodies
Six-week-old female BALB/c mice were immunised subcu-
taneously with 100 μg RAI3 liposomes and 60 μl GERBU
Adjuvant MM (GERBU Biochemicals, Gaiberg, Germany)
as a priming injection following three booster injections
with 50 μg RAI3 mixed with 40 μl adjuvant at 10-day
intervals. Two days prior to fusion, a final booster injec-
tion was given comprising 50 μg RAI3 without adjuvant.
On each day of immunisation a 10-μl blood sample was
taken to monitor the specific antibody titre in the serum.
The immune response was analysed by direct ELISA using
plates coated with recombinant RAI3 protein (50 ng/well)
and a HRP-conjugated anti-mouse IgG antibody (Sigma-
Aldrich, Munich, Germany; 1:5,000) using a serial dilu-
tion of mouse serum.
On day 45, the spleen was dissected and spleen cells were
fused with murine myeloma SP2-IL6 cells (ATCC: CRL-
2016 [11]) at a ratio of 1:1 in the presence of PEG 1500
(Boehringer, Mannheim, Germany). Fused cells were cul-
tured and selected in RPMI 1640 (Gibco Invitrogen,
Carlsbad, USA) supplemented with 20% bovine calf
serum (Biochrom AG, Berlin, Germany), 100 U/ml peni-
cillin, 100 μg/ml streptomycin (Gibco Invitrogen), 100
μM hypoxanthine, 16 μM thymidine, and 0.4 μM ami-
nopterin (Sigma-Aldrich), 80 U/ml murine interleukin-6
(Calbiochen, San Diego, USA) and 50 μM βME (Gibco
Invitrogen) in 96-well microtitre plates. The selectionPage 3 of 15
(page number not for citation purposes)
BMC Cancer 2009, 9:200 http://www.biomedcentral.com/1471-2407/9/200medium was refreshed after one week. After 12 days, cul-
ture supernatants were screened for antibodies binding to
RAI3 liposomes in a direct ELISA. Hybridomas in wells
generating the highest ELISA signals were used for limit-
ing-dilution cloning in HT medium (RPMI 1640 supple-
mented with 20% bovine calf serum, 100 U/ml penicillin,
100 μg/ml streptomycin, 100 μM hypoxanthine, 16 μM
thymidine, 80 U/ml interleukin-6 and 50 μM βME). Mon-
oclonal hybridomas were cultured in standard growth
medium (RPMI 1640 supplemented with 10% bovine calf
serum, 100 U/ml penicillin, 100 μg/ml streptomycin).
Prior to purification, hybridomas were adapted to serum-
free hybridoma culture medium ISF-1 (Biochrom AG).
Antibodies were purified from culture supernatants by
Protein-G affinity chromatography (ÄKTAFPLC systems,
Amersham Biosciences, Freiburg, Germany). Isotypes
were determined using a BD Bioscience (Heidelberg, Ger-
many) isotyping kit (Heidelberg, Germany). Clone 24 2.3
was selected for immunohistochemical analysis.
Direct ELISA for the analysis of hybridoma supernatants
Hybridoma supernatants containing monoclonal anti-
RAI3 antibodies were analysed by direct ELISA. High-
binding microtitre plates (Greiner Bio-One, Fricken-
hausen, Germany) were coated overnight at 4°C with var-
ying amounts of recombinant RAI3 (0.2–200 ng/well) in
100 mM carbonate buffer (pH 9.5), or with 50 ng/well of
the negative control proteins bovine serum albumin
(BSA), an unrelated human protein (CD30 ligand), and a
control GPCR (GPR30) produced under the same condi-
tions as RAI3. Uncoated wells were used as an additional
negative control. After blocking with 2% non-fat dry milk,
50 μl hybridoma supernatant was added directly to each
well and incubated at room temperature for 1 h. Plates
were washed three times with phosphate buffered saline
containing 0.05% Tween20 (PBST). The binding of anti-
RAI3 antibodies was detected with a HRP-conjugated anti-
mouse antibody (Sigma-Aldrich; 1:5,000) and 2'-azino-
bis(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS)
(Roche Diagnostics, Mannheim, Germany) as the sub-
strate. Absorption was measured at 405 nm using an
ELISA reader (Biotek Instruments, Bad Friedrichshall, Ger-
many). Each measurement as performed in triplicate.
Measuring binding affinity
The binding affinity of purified monoclonal antibodies
was estimated in a competitive ELISA [12]. Briefly, high-
binding microtitre plates were coated overnight at 4°C
with 50 μl of the 1 μg/ml protein solutions described
above. After blocking, a 1 nM antibody solution was pre-
incubated with a serial dilution of RAI3 antigen in the
molar range 2 × 10-8–2 × 10-10M until equilibrium was
achieved. The antibody-antigen mixture was then applied
to the coated microtiter plate in triplicate, to measure the
unbound antibodies remaining in solution. The immobi-
lised antibodies were detected and quantified as described
for the direct ELISA. Kd values were calculated from the
absorption data as described elsewhere [12].
Transfection of mammalian cells
RAI3 template DNA was kindly provided by M-Fold Bio-
tech, Tübingen, Germany. The DNA was amplified with
gene-specific primers containing appropriate restriction
sites for cloning in pMS RAI3 III and pMS GFP-RAI3 MH,
allowing RAI3 to be expressed under the CMV promoter
with and without C-terminal GFP. The primers were NheI
Kozak 5' (5'-cat tcg agG CTA Gcc acc ATG GCT ACA ACA
GTC CCT G-3'), NotI 3' (5'-act tgt caG CGG CCG CGC
TGC CCT CTT TCT TTA CTT C-3') and SfiI 5' (5'-cat tcg
agG GCC CAG CCG GCC ATG GCT ACA ACA GTC CCT
G-3'). Restriction sites are underlined, small roman letters
are anchor sequences and italic letters show the Kozak
consensus. Mock expression vectors with and without
GFP were generated as controls. HEK 293T cells (ATCC:
CRL-11268) were cultured in RPMI 1640 supplemented
with 10% bovine calf serum, 100 U/ml penicillin and 100
μg/ml streptomycin and transfected using Roti-fect (Carl
Roth GmbH, Karlsruhe, Germany) according to the man-
ufacturer's protocol. Transfected cells were selected by
supplementing the medium with 100 μg/ml zeocin (Inv-
itrogen).
Western blot analysis of cell lysates
RAI3-transfected and mock-transfected HEK293T cells
were harvested and agitated for 30 min at 4°C in a non-
denaturing lysis buffer (20 mM Tris HCl (pH 8), 137 mM
NaCl, 10% glycerol, 2 mM EDTA, 1% Triton X-100) con-
taining a freshly added protease inhibitor cocktail tablet
(Roche Diagnostics). The insoluble fraction was separated
by centrifugation for 20 min at 12,000 × g. Cell lysates
containing approximately 10 μg total protein were sepa-
rated by sodium dodecylsulphate polyacrylamide gel elec-
trophoresis (SDS-PAGE) on a 12% polyacrylamide gel
and blotted to nitrocellulose membranes (Whatman Sch-
leicher & Schuell, Dassel, Germany). Membranes were
blocked for 1 h at room temperature in PBST containing
2% non-fat dry milk, washed three times in PBST and
incubated with anti-RAI3 antibodies (100 ng/ml in PBST)
overnight at 4°C. After three PBST washes, the mem-
branes were incubated with HRP-conjugated anti-mouse
antibody (Sigma-Aldrich; 1:5000 in PBST) for 1 h at room
temperature, followed by three further washes. Specific
binding was detected with ECL Western Blotting substrate
(Pierce, Rockford, USA) and visualised in a LAS-3000
imager (Fujifilm). The blot was subsequently stripped by
incubation in stripping buffer (62.5 mM Tris (pH 6.8),
2% SDS, 100 mM βME) for 45 min at 50°C. For loading
control, the blot was reprobed with an HRP-conjugated
anti-β-actin antibody (Sigma-Aldrich; 1:2000) and
detected with the ECL system as described above.Page 4 of 15
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The specificity of the anti-RAI3 antibody (Mab 24 2.3) was
further analysed by immunocytochemistry in HEK293T
cells. Briefly, HEK293T cells transiently transfected with
the expression vector encoding RAI3-GFP were seeded at
2.5 × 104 cells per well on a multi-well chamber slide
(Nunc) and incubated overnight at 37°C to allow cells to
attach. Cells were fixed in 4% paraformaldehyde, washed
with PBS and subsequently permeabilised and blocked in
PBS containing 0.5% Triton X-100 and 3% BSA. Follow-
ing a washing step, the primary anti-RAI3 antibody Mab
24 2.3 was applied in a 1:100 dilution and incubated on
the cells for 1 h at room temperature. Primary antibody
binding was detected indirectly using a 1:2000 dilution of
AlexaFluor-546 conjugated anti-mouse secondary anti-
body (A546; Invitrogen) which was incubated on the cells
in the dark for 1 h at room temperature followed by a fur-
ther washing step. The primary antibody was omitted in
control cells. The cell nucleus was stained post fixation
using a 20 μM Draq5 solution (Biostatus) in PBS followed
by a final washing and a second fixation step. Images of
the cells were acquired by confocal microscopy.
Laser scanning confocal microscopy
Imaging was carried out by laser scanning confocal micro-
scopy using 488, 561 and 635 nm excitation laser lines
and tunable emission filters adjusted to cover emission
ranges between 540/75, 600/40 and 685/70 nm for RAI3-
GFP, AlexaFluor-546 and Draq5, respectively. Images of
cells labelled with the three fluorophores were acquired
using a 40× PlanApo air objective (0.85 numerical aper-
ture) and sequential acquisition to prevent measuring
"cross-talk" between the three emission signals. The
images were pseudo coloured in Adobe Photoshop.
Patient samples
RAI3 protein expression in breast cancer patients was
assessed using a previously-described tissue microarray
(TMA) [13] comprising 157 breast cancer specimens and
44 normal breast tissue samples. The TMA contained one
tissue core from non-selected, formalin-fixed and paraf-
fin-embedded primary breast cancer from patients aged
25–82 (median age of 56), diagnosed between 1994 and
2002 at the Institute of Pathology, University of Regens-
burg, Germany. An experienced surgical pathologist
(A.H.) evaluated H&E-stained slides of all specimens prior
to construction of the TMA in order to identify represent-
ative tumour areas. All tumours were graded according to
Elston and Ellis [14]. Clinical follow-up data, provided by
the Central Tumour Registry, Regensburg, Germany, were
available for all 157 breast cancer patients with a median
follow-up period of 78 months (range 0–148 months).
All patients gave informed consent for retention and anal-
ysis of their tissue for research purposes and the Institu-
tional Review Board of the participating centre approved
the study.
Breast cancer cDNA dot blot hybridisation
The breast cancer profiling array (CPA) (BD Clontech,
Heidelberg, Germany) contains 50 pairs of cDNAs gener-
ated from matched cancerous and normal breast tissue
samples of individual patients and three breast cancer
lymph node metastasis specimens, spotted on a nylon
membrane [15]. Hybridisations using 25 ng of a gene-spe-
cific 32P-labelled cDNA probe prepared from a RAI3 Uni-
gene cDNA clone were carried out according to the
manufacturer's recommendations. This hybridisation
probe included base pair 550 to 2835 of the RAI3 cDNA
deposited under accession number NM_003979. The
tumour/normal intensity ratio was calculated using a
STORM-860 phosphorimager (Molecular Dynamics, Sun-
nyvale, CA, USA) and normalised against the background.
Immunohistochemical characterisation of the tissue 
microarray
Immunohistochemical studies of HER2 expression were
carried out using the avidin-biotin peroxidase method
with a 3,3'-diaminobenzidine (DAB) chromogen in a
NEXES immunostainer (Ventana, Tucson, AZ, USA) fol-
lowing antigen retrieval by microwaving for 30 min. Pri-
mary anti-HER2 (DAKO, Hamburg, Germany; 1:400),
anti-ER and anti-PR (Novocastra, Newcastle Upon Tyne,
UK; 1:20) antibodies were detected using the ChemMate
detection kit (DAKO). A surgical pathologist (A.H.) per-
formed a blinded evaluation of the TMA slides without
clinical data. Non-interpretable results were caused by a
lack of tumour tissue and the presence of necrosis or crush
artefacts. HER2 expression was scored according to the
DAKO HercepTest. For the evaluation of ER and PR, a
semi-quantitative immunoreactivity score (IRS) was used
as described by Remmele and Stegner [16].
RAI3 immunohistochemistry
The tissue microarray was stained using the Advance Kit
(DAKO K5007) according to the manufacturer's instruc-
tions. Breast carcinomas were used as positive controls.
After paraffin removal and rehydration, the tissue samples
were boiled in a microwave oven for 30 min in 10 mM
sodium citrate buffer (pH 7.6). Endogenous peroxidase
was blocked by peroxidase blocking solution (DAKO S
2023) for 10 min. The anti-RAI3 antibody Mab 24 2.3,
was selected for immunohistochemical application. It was
applied at a dilution of 1:50 for 3–4 h at 4°C and detected
with DAB. In negative controls the primary antibody was
omitted. As an additional negative control, a competitive
immunohistochemical analysis was performed by pre-
incubation of the anti-RAI3 antibody Mab 24 2.3 with
200-fold molar excess of RAI3. Slides were counterstained
with haematoxylin and after dehydration mounted inPage 5 of 15
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experienced pathologist (N.B.) scored the immunohisto-
chemical staining intensity according to the scoring sys-
tem suggested devised by Remmele and Stegner [16].
Statistical methods
SPSS version 14.0 (SPSS Inc, Chicago, IL) was used for sta-
tistical evaluation. Differences were considered statisti-
cally significant at P < 0.05. For analysis of the CPA, a
Kolmogorov-Smirnov test was applied to test for normal
value distribution, followed by a two-sided paired t-test to
analyse differences in normal and tumour expression. A
statistical association between clinicopathological and
molecular parameters was tested, using two-sided Fisher's
exact test. Recurrence-free (RFS) and overall survival (OS)
were calculated according to the Kaplan-Meier equation.
Results
Generation and characterisation of monoclonal anti-RAI3 
antibodies
The human RAI3 cDNA was expressed in bacteria and the
protein isolated from inclusion bodies and reconstituted
into liposomes for immunisation of BALB/c mice. The
specific antibody titre during immunisation was moni-
tored by analysing blood samples using a direct ELISA
(Figure 1A), allowing the optimum time point for the
fusion of spleen cells to be selected. The antibody titre
began to increase 21 days after the first immunisation.
Between day 21 to day 30, the titre increased from 1: 3000
to 1: 30,000 indicating a good secondary immune
response to the recombinant, liposome-integrated pro-
tein. Spleenocyte fusion was carried out on day 45, fol-
lowed by limiting dilution cloning and screening to yield
four monoclonal antibodies against RAI3 for further char-
acterisation.
Analysis of hybridoma supernatants by direct ELISA
showed that they contained antibodies with high specifi-
city for recombinant RAI3 protein, as revealed by the
strong correlation between the amount of coated RAI3
and the absorption signal (Figure 1B). There was no cross
reactivity to bovine serum albumin (BSA), the CD30 lig-
and (an unrelated human protein) or GPR30 (a control
human GPCR). Isotyping showed that all four clones pro-
duced IgG1 antibodies (Table 1) thus prompting our deci-
sion to use protein-G affinity chromatography to purify
the antibodies from serum-free hybridoma supernatants.
A competitive ELISA confirmed specific binding of the
purified antibodies to recombinant RAI3 in solution (Fig-
ure 1C) and was used to calculate binding affinity con-
stants, which were all in the nanomolar range (Table 1).
Western blots on lysates from transfected HEK 293T cells
confirmed antibody binding to soluble proteins in cells
expressing RAI3 and RAI3-GFP but not to soluble proteins
in mock-transfected cells (Figure 1D). However, these
experiments did not resolve a single distinct band corre-
sponding to the predicted molecular weight of RAI3 (~40
kDa) or its GFP fusion (~67 kDa) despite the general good
quality of the lysates demonstrated by the β-actin positive
control. This probably reflects aggregation of RAI3, a com-
mon problem with hydrophobic proteins, as well as the
presence of different glycoforms and perhaps also proteo-
lytic degradation products. Aggregation was also observed
in western blots using the purified protein (data not
shown). However, specificity becomes clear as these pat-
terns can also be found in lane 3 (GFP fusion) except that
the bands in total indicate a protein of a higher molecular
weight due to the fusion to GFP. To further confirm RAI3
specificity, we performed immunocytochemistry on
HEK293T cells transiently transfected with the expression
vector encoding recombinant RAI3-GFP followed by con-
focal microscopy analysis. The transient transfection pro-
duced a heterogeneous population of green fluorescent
RAI3-GFP transfected cells and non-fluorescent untrans-
fected cells. This allowed analysis of both cell types within
the same cell preparation. Figure 2 (upper panels) clearly
shows that the GFP signal of the recombinant receptor
and the indirect A546 detection signal of the Mab 24 2.3
anti-RAI3 antibody largely co-localised in transiently
transfected HEK293T cells (yellow signal in the merge
panel). Interestingly, the non transfected cells did not
show any signal which could be ascribed to detection of
the endogenous RAI3 receptor by the anti-RAI3 antibody
(upper panels of Figure 2). Transfected control HEK293T
cells treated with the A546 secondary antibody alone did
not display background signals which excluded unspecific
binding of the secondary antibody (Figure 2 lower pan-
els). This result confirmed the specificity of the anti-RAI3
antibody in detecting the RAI3 receptor in cells.
Of the four highly-specific antibodies we produced, Mab
24 2.3 was also selected for further immunohistochemical
experiments because it showed the cleanest and most
intense staining (data not shown).
Upregulation of RAI3 in primary breast cancer analysed by 
cDNA dot blot hybridisation
RAI3 upregulation was demonstrated by dot blot analysis
on a nylon array containing spotted cDNAs derived from
50 matched pairs of normal and tumourous breast tissue
(Figure 3). The cancer profiling array showed upregula-
tion (fold change ≥ 2) of RAI3 in 30 of 50 primary breast
tumours (60%), and in one of three metastatic lymph
nodes, compared with matched normal breast tissue
(two-sided paired t-test: P < 0.001). The mean densito-
metric intensity in normal tissues was 1600 arbitrary units
(standard deviation (SD) ± 818) and 3139 (SD ± 1453)
arbitrary units in tumour tissues. Downregulation of RAI3
in normal/tumour sample pairs could not be detected.Page 6 of 15
(page number not for citation purposes)
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via Nothern blot and cDNA dot blot controls (see Addi-
tional files 1 and 2).
Expression of RAI3 protein in primary breast carcinomas
A large tissue microarray was used to investigate the abun-
dance of cytoplasmic and membrane-bound RAI3 in
Characterisation of monoclonal anti-RAI3 antibodiesFigure 1
Characterisation of monoclonal anti-RAI3 antibodies. A:. Direct ELISA of a serial dilution of BALB/c mouse serum car-
ried out at several time points during immunisation. Increasing antbody titre indicates a good humoral immune response. Meas-
urements are from triplicates, expressed as means ± S.D. B: Direct ELISA of hybridoma supernatants from four selected 
monoclones showing a concentration dependent RAI3 signal and no cross-reactivity to control proteins. BSA: bovine serum 
albumin; CP1: control protein 1, non-related human protein (CD30 ligand); CP2: control protein 2, related human protein, 
GPCR (GPR30); No: Negative control, no protein coated. Measurements are from triplicates, expressed as means ± S.D. C: 
Competitive ELISA of Mabs pre-incubated with a serial dilution of soluble antigen RAI3. Only unbound antibody can bind to the 
immobilised antigen on the ELSA plate allowing the comparison and determination of affinities based on the absorption values. 
Measurements are from triplicates, expressed as means ± S.D. D: Western blot analysis of cell extracts from transfected 
HEK293T cells. Cells expressed either RAI3 (lane 1), mock protein (lane 2), RAI3-GFP (lane 3) or mock-GFP protein (lane 4). 
Aliquots (10 μg) of total protein from cell extracts are loaded as indicated, with β-actin as the loading control. At least three 
experiments for Mab 24 2.3 are represented. Equal binding pattern was observed in all experiments.Page 7 of 15
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sue specimens (n = 44). Although the median IRS was 4 in
both the tumour and normal tissue samples, RAI3 protein
levels differed between normal breast tissue and tumours.
In normal breast epithelial cells, including myoepithelial
cells, RAI3 was often weakly expressed compared to inva-
sive breast carcinoma (Figure 4A and 4B). In ductal carci-
noma, in situ RAI3 expression was confined to the
malignant epithelial cells and was often weaker than in
invasive breast carcinoma (Figure 4C and 4D). In invasive
ductal breast carcinomas, RAI3 was often generally more
abundant in the cytoplasm and in the cell membrane than
in either ductal carcinoma in situ or normal breast tissue
(Figure 4E and 4F, ductal type). In tubular breast carcino-
mas, a less frequent variant of invasive breast carcinomas
with a more favourable prognosis than invasive ductal
breast carcinomas, RAI3 protein was expressed less abun-
dantly than in most invasive ductal breast carcinomas
(Figure 4G and 4H). In mucinous breast carcinomas,
another less frequent variant of invasive breast carcino-
mas with a more favourable prognosis than invasive duc-
tal breast carcinomas, RAI3 expression was also less
abundant in comparison to most invasive ductal breast
carcinomas (Figure 4I and 4J). Specificity of the immuno-
histochemical analysis has been demonstrated by a com-
petitive approach (Figure 5). Staining was greatly reduced
by pre-incubating the anti-RAI3 antibody with 200-fold
molar excess of recombinant RAI3 protein (Figure 5C, D)
compared to staining without competitor (Figure 5A, B).
Correlation between RAI3 expression and 
clinicopathological patient parameters
For statistical analysis cytoplasmic/membrane-bound
RAI3 protein with an IRS ≥ 5 was considered as 'abundant'
whereas an IRS range of 0–4 was considered 'low'. RAI3
expression was not associated with tumour stage, lymph
node status, histological grading, focality or histological
tumour type (Table 2). Furthermore, RAI3 was neither
associated with the presence of the oestrogen receptor (P
= 0.557) nor the progesterone receptor (P = 0.765).
Finally, we observed no association between RAI3 expres-
Table 1: Monoclonal anti-RAI3 antibodies, overview isotypes and 
affinity values
Antibody Isotype Kd value [nM]
24 2.1 IgG1, kappa 2,2 ± 0,4
24 2.2 IgG1, kappa 1,8 ± 0,9
24 2.3 IgG1, kappa 2,3 ± 0,3
24 3.1 IgG1, kappa 2,7 ± 1,2
Immunocytochemistry analysis of HEK293T cells expressing RAI3-GFPFigure 2
Immunocytochemistry analysis of HEK293T cells expressing RAI3-GFP. Transiently transfected HEK293T cells 
expressing RAI3-GFP were subjected to immunocytochemistry analysis. The upper panels (anti-RAI3) show transfected cells 
incubated with anti-RAI3 antibody and subsequently with anti mouse AlexaFluor 546-labelled secondary antibody (A546). The 
immunostaning is pseudo-coloured in red. Co-localisation of the RAI3-GFP and A546 signals is shown in yellow in the merge 
panel. For the transfected control cells (Control panels) primary anti-RAI3 antibody was omitted in order to exclude unspecific 
binding of the A546 secondary antibody. Nuclei were stained using Draq5 and are pseudo-coloured in blue. Imaging was car-
ried out by confocal microscopy using a 40× air objective. Scale bar: 20 μmPage 8 of 15
(page number not for citation purposes)
BMC Cancer 2009, 9:200 http://www.biomedcentral.com/1471-2407/9/200sion and high expression of the HER2 receptor as deter-
mined by immunohistochemistry (DAKO score 3+; P =
0.638) (Table 2).
Prognostic impact of RAI3 expression
To investigate the impact of RAI3 overexpression on
patients' clinical outcome, we calculated univariate sur-
vival probability curves with respect to the immunohisto-
chemistry results. We found that abundant RAI3
expression in breast cancer (IRS ≥ 5) was not associated
with significant alterations in the outcome regarding over-
all (P = 0.816) and recurrence-free (P = 0.897) survival as
shown by Kaplan-Meier analysis (Table 3). The other fac-
tors established in clinical routine, including tumour
stage, lymph node status, histological grading as well as
the status of the hormone receptors and HER2, show sig-
nificant correlations in overall and/or recurrence-free sur-
vival analysis, underlining the fact that the set of breast
carcinomas used in our investigation was not biased
(Table 3).
Discussion
We generated four monoclonal antibodies against the
human GPCR RAI3 and carried out a systematic analysis
of RAI3 expression in human breast cancer. Members of
the GPCR superfamily are known to be involved in the
regulation of many physiological processes including cell
growth and differentiation, and are therefore regarded by
the pharmaceutical industry as interesting therapeutic tar-
gets [1,17,18]. In terms of antibody generation, GPCRs in
general are often considered as difficult antigens since the
expression and purification of the recombinant protein is
a challenging approach that limits the availability of the
protein [10,19,20]. We have overcome this challenge by
combining recombinant protein expression in bacteria
with a technique for reformulating the RAI3 protein in
liposomes prior to immunisation, allowing the genera-
tion of monoclonal antibodies using standard hybridoma
technology. Only polyclonal antibodies against RAI3 are
commercially available, so our work represents an impor-
tant step forward, i.e. the first monoclonal anti-RAI3 anti-
bodies. Monoclonal antibodies are more suitable as
therapeutics because nonspecific cross-reactions are less
likely to occur. Furthermore, the quality of polyclonal
antibodies may vary considerably between batches
whereas monoclonal antibodies, which originate from a
single cell, are more consistent. Among four independent
monoclonal antibodies generated by hybridoma technol-
ogy, we selected Mab 24 2.3 for further immunohisto-
chemical experiments as it provided the clearest signals
and was able to detect RAI3 in formaldehyde-fixed, paraf-
fin-embedded tissues which makes it easily applicable in
the clinicopathological routine.
To determine whether Mab 24 2.3 was useful for the char-
acterisation of human breast carcinomas, we carried out a
systematic analysis of breast cancer and normal breast tis-
sue on a tissue microarray. Previous studies have shown
that RAI3 mRNA is upregulated in several breast cancer
tissues and cell lines [5,7,9] but there has been no similar
study at the protein level because of the lack of useful rea-
gents and a immunohistochemical characterisation of the
RAI3 protein in normal and breast cancer tissue has not
been published. The systemic analysis of RAI3 protein
expression in human breast cancer tissue is interesting
because the protein has been proposed as membrane-
bound [3], making it a potential therapeutic target as well
as a useful biomarker. The most prominent therapeutic
monoclonal antibody is Herceptin® (trastuzumab) which
is indicated for breast cancers involving the upregulation
of HER2, a receptor tyrosine kinase belonging to the epi-
dermal growth factor receptor (EGFR)/HER family [21].
Upregulation of HER2 is observed in 10–34% of invasive
breast tumours and offers a poor prognosis. The HER2 sta-
cDNA dot blot analysis of RAI3 expression in matched normal and t breast tissueFigure 3
cDNA dot blot analysis of RAI3 expression in matched normal and t breast tissue. Expression profiles were deter-
mined using cDNA dot blot hybridisation analysis (BD Clontech) containing cDNA pairs derived from 50 matched normal 
breast tissues (N), tumourous breast tissues (T), and three lymph node metastastic tissues (marked with arrows). Upregulation 
of RAI3 was observed in 30 of 50 primary breast tumours as well as in one of three metastatic lymph nodes, as compared to 
matched normal breast tissue.Page 9 of 15
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RAI3 Immunohistochemistry on TMA derived from normal and cancerous breast tissueFigure 4
RAI3 Immunohistochemistry on TMA derived from normal and cancerous breast tissue. Immunohistochemical 
expression analysis of RAI3 in normal breast tissue as well as non-invasive and invasive breast tumours using a tissue microar-
ray. (A, B) In normal breast epithelial cells RAI3 expression (IRS = 8) was often weaker than in invasive breast carcinoma cells. 
(C, D) In ductal carcinoma in situ RAI3 expression (IRS = 3) was often less intense compared to invasive breast carcinoma. (E, 
F) In invasive breast carcinomas (here: ductal type) RAI3 was often expressed more abundantly in the cytoplasm and in the cell 
membrane (example shows staining with an IRS = 12) than in either ductal carcinoma in situ or normal breast tissue. (G, H) In 
tubular breast carcinomas, RAI3 expression was less abundant (IRS = 3) than in most invasive ductal breast carcinomas. (I, J) In 
mucinous breast carcinomas, RAI3 expression was also less intense (IRS = 1) in comparison to most invasive ductal breast can-
cer cells. Magnifications: A, C, E, G, I: 40×; B, D, F, H, J: 400×.
BMC Cancer 2009, 9:200 http://www.biomedcentral.com/1471-2407/9/200tus of a breast cancer patient is therefore a very important
clinical indicator used to select a therapeutic strategy, and
HER2-positive breast tumours are often treated with Her-
ceptin®. Nevertheless, most patients develop resistance to
Herceptin during therapy [22], so the discovery of addi-
tional biomarkers and potential therapeutic targets is of
great interest, since this provides scope for novel or com-
bined therapies in Herceptin-resistant tumours. RAI3 may
be such a candidate molecule and monoclonal antibodies
against RAI3 could be used in diagnosis and in the treat-
ment of breast cancer. However, because the function of
RAI3 in normal and malignant cells is poorly understood
and controversial [5,6,8], a thorough analysis of its
expression in human breast cancer tissue is necessary prior
to further development. Expression of RAI3 in human
cancerous and normal breast tissue has not been analysed
by immunohistochemistry, thus far. In the current study,
a systematic characterisation of RAI3 expression in human
cancerous and normal breast tissue, both at the cDNA and
the protein level, is here provided for the first time.
In a previous study [6], RAI3 mRNA levels were measured
by quantitative RT-PCR in the normal mammary cell lines
HMEC 50 and HMEC 21 as well as in the malignant breast
epithelial cell lines MDA-MB-468, BT-20, BT-549, SK-BR-
3, T47D, MCF7, ZR-75-1 and BT474. Upregulation of
RAI3 mRNA (50%) was observed in the oestrogen recep-
tor-negative breast cancer cell lines MDA-MB-468, BT-20,
BT-549, SK-BR-3 compared to the normal mammary cell
lines HMEC 50 and HMEC 21. However, we could not
detect a significant correlation between RAI3 expression
and the hormone receptor status in our analysis. Further-
more, similar results indicating RAI3 upregulation were
obtained in a small set of lung, colon and pancreas cell
lines, compared to one sample originating from normal
tissue [6]. The overexpression of RAI3 in human breast
cancer was also shown by Nagahata et al. [5,9]. Quantita-
tive RT-PCR also showed that RAI3 levels were higher in
19 out of 25 primary breast cancers compared to matched
normal tissues and in 6 of 11 breast cancer cell lines and
in HEK293 cells [5]. In our study, we confirmed RAI3
mRNA overexpression by cDNA dot blot analysis, show-
Competitive RAI3 Immunohistochemistry on cancerous breast tissueFigur  5
Competitive RAI3 Immunohistochemistry on cancerous breast tissue. Immunohistochemical staining of cancerous 
breast tissue (A, B) in comparison to a competitive immunohistochemical approach (C, D). Strong staining of tumourous tissue 
was observed using a 1:50 dilution of anti-RAI3 Mab 24 2.3 (A, B). Staining is inhibited by pre-incubation of the antibody with 
200-fold molar excess of recombinant RAI3 protein (C, D). Magnifications: A, C: 200×; B, D: 400×.Page 11 of 15
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matched human breast carcinomas compared to the cor-
responding normal breast tissues. However, we did not
observe similar upregulation at the protein level based on
immunohistochemical analysis of a TMA. Here we ana-
lysed a large cohort of 157 breast cancer specimens and 44
normal breast tissue specimens that were not matched.
The median IRSs for normal and cancerous breast tissues
showed no statistically significant difference. A possible
explanation for the discrepancy between the mRNA and
protein results may be the presence of larger amounts of
connective tissue in normal tissue samples compared with
the corresponding tumour tissue samples. Thus, RNA
preparations from such samples would contain an excess
of mRNA originating from RAI3-negative connective tis-
sue, resulting in lower overall signal levels compared to
the tumour samples, a phenomenon that could also have
affected previous RNA-based studies of breast cancer. In
an immunohistochemical approach like the TMA, only
normal and cancerous epithelial cells are compared
directly, so the presence of connective tissue does not
influence the result. Furthermore, we cannot exclude the
possibility of posttranscriptional regulation of the RAI3
gene. In such a case, translation of mRNA into protein
may be inhibited which would result in discordant mRNA
and proteins levels [23]. This could also explain the fact
that we could not detect endogenous RAI3 in HEK 293T
by western blot and immunocytochemistry analysis of
untransfected cells (see Additional file 3). Another expla-
nation for this discrepancy may be clonal differences in
the used cell lines from different laboratories. There is a
tremendous number of different factors that could
account for changes of the physiological status of cells and
can affect the expression levels of certain proteins, e.g. age
of the cells, numbers of passages, cell culture medium,
supplements, etc. [24]. In addition, it should be noted
that RAI3 expression data derived from cells cultured in
vitro is liable to misinterpretation because RAI3 is induced
Table 2: Clinicopathological and immunohistochemical parameters in relation to RAI-3 immunoreactivity
Variable Categorisation RAI-3 immunoreactivity
n analysable lowb abundantb pc
Clinicopathological data:
Tumour stagea
pT1 46 29 17 0.134
pT2 74 31 43
pT3 12 5 7
pT4 24 13 11
Lymph node statusa
pN0 68 34 34 0.713
pN1-3 83 44 39
Histological grade
G1 16 9 7 0.572
G2 67 36 31
G3 72 33 39
Multifocality
unifocal tumour 130 69 61 0.086
multifocal tumour 26 9 17
Histological type
ductal 130 66 64 0.905
lobular 11 5 6
other 13 6 7
Immunohistochemistry (IHC):
Oestrogen receptor status
negative (IRS 0–2) 41 23 18 0.557
positive (IRS 3–12) 89 45 44
Progesterone receptor status
negative (IRS 0–2) 95 46 49 0.765
positive (IRS 3–12) 41 21 20
HER2 status
weak (0–2+) 109 51 58 0.638
strong (3+) 25 13 12
aAccording to UICC: TNM Classification of Malignant Tumours. 6th edn (2002) Sobin LH, Wittekind CH (eds) Wiley: New York
bRAI-3 immunoreactivity: low = IRS 0–4, abundant = IRS 5–12
cPearson test (two-sided), bold face representing significant data (P < 0.05)Page 12 of 15
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medium. This could introduce a bias if normal cells are
cultivated under different conditions, e.g. without serum
[25]. However, such factors can be excluded from our
analysis because we used tissue samples rather than cell
lines.
A cDNA microarray and RT-PCR study of 20 oestrogen
receptor-negative breast cancers identified RAI3 as one of
the genes indicating poor patient survival (RAI3 was
upregulated in the group of 10 patients who had died of
breast cancer within 5 years after surgery [9]). Genuine
RAI3 upregulation has to be questioned as the authors
used a very small collection of breast cancer specimens. In
our study, using a TMA containing a much larger set of
breast carcinomas, we found no significant correlation
between RAI3 expression and overall or recurrence-free
survival.
The ambiguous role of RAI3 in oncogenesis is underlined
by studies that indicate RAI3 is a tumour suppressor gene
in lung cancer, based on increased lung tumour preva-
lence in RAI3 knock-out mice [8]. Additionally, RAI3
mRNA levels were reduced in 11 of 18 human lung cancer
samples compared to adjacent normal tissue samples. In
our study, we found no evidence in either the CPA or TMA
experiments of RAI3 downregulation in human breast car-
cinoma. The RAI3 protein was distributed heterogene-
ously throughout the normal breast tissue and tumour
samples. Therefore, whether RAI3 could be a target for
future breast cancer therapy is still unclear. Further studies
in larger cohorts of matched normal breast and tumour
Table 3: Univariate analysis of factors regardingoverall survival (OS) and recurrence-free survival (RFS)
Variable Categorisation Tumour-related death (OS) Tumour recurrence (RFS)
n events pc n events pc
Clinicopathological data:
Tumour stagea
pT1 46 7 <0.0001 44 8 <0.0001
pT2 74 27 71 32
pT3 12 3 11 4
pT4 24 16 21 13
Lymph node statusa
pN0 68 9 <0.0001 66 13 <0.0001
pN1-3 83 40 79 42
Histological grade
G1 16 4 0.005 15 5 <0.0001
G2 67 16 62 15
G3 72 33 70 37
Multifocality
unifocal tumour 130 43 0.545 123 47 0.689
multifocal tumour 26 10 24 10
Histological type
ductal 130 44 0.787 126 52 0.432
lobular 11 5 9 2
other 13 4 11 3
Immunohistochemistry (IHC):
Oestrogen receptor status
negative (IRS 0–2) 41 17 0.094 41 21 0.034
positive (IRS 3–12) 89 26 84 26
Progesterone receptor status
negative (IRS 0–2) 95 43 <0.0001 88 43 0.001
positive (IRS 3–12) 41 5 41 6
HER2 IHC
weak (0–2+) 109 32 0.006 101 37 0.128
strong (3+) 25 14 25 12
RAI-3b
low (IRS 0–4) 78 25 0.816 76 29 0.897
abundant (IRS 5–12) 78 28 71 28
aAccording to UICC: TNM Classification of Malignant Tumours. 6th edn (2002) Sobin LH, Wittekind CH (eds) Wiley: New York
bRAI-3 immunoreactivity: low = IRS 0–4, abundant = IRS 5–12
cLog-rank test (two-sided), bold face representing significant data (P < 0.05)Page 13 of 15
(page number not for citation purposes)
BMC Cancer 2009, 9:200 http://www.biomedcentral.com/1471-2407/9/200tissues may provide more detailed information about the
upregulation of RAI3 in breast tumours because the
induction of RAI3 was demonstrated in the CPA, which
comprised matched tissue samples. Further functional
studies are also required to determine the receptor's mode
of action and its ligand.
In summary, the novel monoclonal anti-RAI3 antibody
Mab 24 2.3 may be useful in further studies to determine
the potential of RAI3 as a tumour marker. It would be par-
ticularly beneficial to study the expression of the RAI3
protein in large TMAs representing a range of different tis-
sues to gain better insight into the role of RAI3 in human
cancer and to evaluate its potential as a target for anti-
body-based cancer therapy.
Conclusion
We generated a highly specific anti-RAI3 monoclonal
antibody (Mab 24 2.3) which could bind the RAI3 antigen
in cell lysates, cells in culture and paraffin-embedded tis-
sues, making it a useful clinical diagnostic tool. Immuno-
histochemical analysis of normal human breast tissues
and tumours using Mab 24 2.3 showed widespread
expression of the RAI3 protein on a tissue microarray of
human breast carcinomas. Furthermore, we demonstrated
upregulation of RAI3 mRNA in breast tumours using
cDNA dot blot analysis. RAI3 is a potential novel biomar-
ker for breast cancer that might be useful as a therapeutic
target due to its membrane localisation and its association
with cancer cell proliferation. However, we were unable to
establish a correlation between patient survival and RAI3
expression. Therefore, further analysis of the protein is
required using larger cohorts representing a variety of tis-
sues, to reveal the functional role of RAI3 expression in
human cancer.
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